{"id":22437,"date":"2021-03-11T07:31:00","date_gmt":"2021-03-11T00:31:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021031107310022437"},"modified":"2021-03-11T21:37:28","modified_gmt":"2021-03-11T13:37:28","slug":"%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%ae%a3%e5%b8%83%e5%b0%86%e5%9c%a82021%e5%b9%b4%e7%be%8e%e5%9b%bd%e7%99%8c%e7%97%87%e7%a0%94%e7%a9%b6%e5%8d%8f%e4%bc%9a%ef%bc%88aacr%ef%bc%89%e5%b9%b4%e4%bc%9a","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021031107310022437","title":{"rendered":"\u4e9a\u76db\u533b\u836f\u5ba3\u5e03\u5c06\u57282021\u5e74\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u516d\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1419966\/logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e743\u670811\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u7814\u53d1\u4f01\u4e1a&#8211;\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u6d89\u53ca\u4e94\u4e2a\u539f\u521b\u65b0\u836f\u7684\u516d\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u90092021\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\uff0c\u6458\u8981\u5185\u5bb9\u5df2\u5728AACR\u5b98\u7f51\u516c\u5e03\u3002\u672c\u6b21AACR\u5e74\u4f1a\u5c06\u4e8e\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f44\u670810\u65e5-15\u65e5\u30015\u670817\u65e5-21\u65e5\u4ee5\u865a\u62df\u4f1a\u8bae\u5f62\u5f0f\u4e3e\u884c\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u662f\u5168\u7403\u5386\u53f2\u6700\u60a0\u4e45\u3001\u89c4\u6a21\u6700\u5927\u7684\u80bf\u7624\u7814\u7a76\u5b66\u672f\u4f1a\u8bae\u4e4b\u4e00\u3002\u4f1a\u8bae\u5173\u6ce8\u9ad8\u8d28\u91cf\u80bf\u7624\u7814\u7a76\u53ca\u521b\u65b0\u7684\u5404\u4e2a\u65b9\u9762\uff0c\u662f\u5168\u7403\u80bf\u7624\u7814\u7a76\u7684\u7126\u70b9\uff0c\u5c06\u6c47\u96c6\u80bf\u7624\u9886\u57df\u7684\u6700\u524d\u6cbf\u7684\u7814\u7a76\u6210\u679c\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u201c\u5f88\u9ad8\u5174\u516c\u53f8\u7684\u591a\u4e2a\u65b0\u836f\u9879\u76ee\u5df2\u8fde\u7eed\u591a\u6b21\u5165\u9009AACR\u5e74\u4f1a\uff0c\u672c\u6b21AACR\u5c55\u793a\u7684\u6210\u679c\u4e3b\u8981\u805a\u7126\u4e8e\u516c\u53f8\u591a\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u7684\u91cd\u8981\u54c1\u79cd\u7684\u8f6c\u5316\u7814\u7a76\u3002\u8fd9\u4e9b\u7814\u7a76\u6709\u52a9\u4e8e\u6211\u4eec\u66f4\u597d\u5730\u4e86\u89e3\u836f\u7269\u4f5c\u7528\u673a\u5236\u3001\u786e\u5b9a\u6709\u6548\u7684\u8054\u5408\u5e94\u7528\uff0c\u4ee5\u53ca\u53d1\u73b0\u65b0\u7684\u9002\u5e94\u75c7\uff0c\u4ece\u800c\u8fdb\u4e00\u6b65\u63a8\u8fdb\u516c\u53f8\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\u3002\u201d<\/p>\n<p><u>\u4e9a\u76db\u533b\u836f\u516d\u9879\u7814\u7a76\u6210\u679c\u5165\u9009<\/u><u>AACR\u58c1\u62a5\u5c55\u793a\u5982\u4e0b\uff1a<\/u><\/p>\n<p>\u6807\u9898\uff1a <\/p>\n<p><b>BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) synergistically induces apoptosis and inhibits tumor growth in preclinical models of acute myeloid leukemia and myelodysplastic syndromes (AML\/MDS)<\/b><\/p>\n<p><b>BCL-2\u6291\u5236\u5242APG-2575\u548c\u9ad8\u4e09\u5c16\u6749\u916f\u78b1(HHT)\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u548c\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81(MDS)\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u8bf1\u5bfc\u7ec6\u80de\u51cb\u4ea1\u548c\u6291\u5236\u80bf\u7624\u751f\u957f\u7684\u534f\u540c\u4f5c\u7528<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\/\u6d77\u62a5\u7f16\u53f7\uff1a981 <\/li>\n<li>\u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5 <\/li>\n<li>\u5206\u4f1a\u573a\u6807\u9898\uff1aCell Death Pathways and Treatment<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u4e0e\u6cbb\u7597<\/li>\n<\/ul>\n<p>\u6807\u9898\uff1a <\/p>\n<p><b>Inhibition of BCL-2 (by APG-2575) and CDK4\/6 synergistically induces cell cycle arrest and apoptosis in ER<\/b><b>\u207a<\/b><b>&nbsp;breast cancer<\/b><b>&nbsp;<\/b><\/p>\n<p><b>BCL-2\u6291\u5236\uff08APG-2575\uff09\u4e0eCDK4\/6\u6291\u5236\u534f\u540c\u8bf1\u5bfcER<\/b><b>\u207a<\/b><b>\u4e73\u817a\u764c\u7ec6\u80de\u7684\u5468\u671f\u963b\u6ede\u548c\u7ec6\u80de\u51cb\u4ea1<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\/\u6d77\u62a5\u7f16\u53f7\uff1a976 <\/li>\n<li>\u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5 <\/li>\n<li>\u5206\u4f1a\u573a\u6807\u9898\uff1aCell Death Pathways and Treatment<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u4e0e\u6cbb\u7597<\/li>\n<\/ul>\n<p>\u6807\u9898\uff1a <\/p>\n<p><b>FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)<\/b><\/p>\n<p><b>FMS\u6837\u916a\u6c28\u9178\u6fc0\u91763 (FLT3) \u6291\u5236\u5242\u5965\u745e\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u901a\u8fc7\u4e0b\u8c03MCL-1\u4e0eBCL-2\u6291\u5236\u5242APG-2575\u5728FLT3\u7a81\u53d8\u578b\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5(AML)\u7684\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u534f\u540c\u4f5c\u7528<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\/\u6d77\u62a5\u7f16\u53f7\uff1a1096 <\/li>\n<li>\u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5 <\/li>\n<li>\u5206\u4f1a\u573a\u6807\u9898\uff1aDrug Resistance in Molecular Targeted Therapies<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5206\u5b50\u9776\u5411\u6cbb\u7597\u7684\u8010\u836f\u6027<\/li>\n<\/ul>\n<p>\u6807\u9898\uff1a<\/p>\n<p><b>Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors<\/b><\/p>\n<p><b>\u51cb\u4ea1\u6291\u5236\u86cb\u767d<\/b><b>(IAP)\u6291\u5236\u5242APG-1387\u8054\u5408DR5\u6fc0\u52a8\u5242CTB-006\u5355\u514b\u9686\u6297\u4f53(mAb)\u5728\u5b9e\u4f53\u7624\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u6cbb\u7597\u6f5c\u529b\u7814\u7a76<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\/\u6d77\u62a5\u7f16\u53f7\uff1a1924 <\/li>\n<li>\u5206\u4f1a\u573a\u7c7b\u522b\uff1aMolecular and Cellular Biology \/ Genetics<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5206\u5b50\u548c\u7ec6\u80de\u751f\u7269\u5b66\/\u9057\u4f20\u5b66 <\/li>\n<li>\u5206\u4f1a\u573a\u6807\u9898\uff1aApoptosis<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u7ec6\u80de\u51cb\u4ea1<\/li>\n<\/ul>\n<p>\u6807\u9898\uff1a&nbsp;<\/p>\n<p><b>Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)<\/b><\/p>\n<p><b>APG-1252 (pelcitoclax)\u6291\u5236 BCL-xL\u514b\u670d\u795e\u7ecf\u5185\u5206\u6ccc\u80bf\u7624(NEN)\u7ec6\u80de\u7684\u51cb\u4ea1\u963b\u65ad\u7814\u7a76<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\/\u6d77\u62a5\u7f16\u53f7\uff1a984 <\/li>\n<li>\u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5 <\/li>\n<li>\u5206\u4f1a\u573a\u6807\u9898\uff1aCell Death Pathways and Treatment<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u4e0e\u6cbb\u7597<\/li>\n<\/ul>\n<p>\u6807\u9898\uff1a <\/p>\n<p><b>Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation<\/b><\/p>\n<p><b>\u5c40\u7076\u7c98\u9644\u6fc0\u9176<\/b><b>(FAK)\u6291\u5236\u5242APG-2449\u901a\u8fc7\u4e0b\u8c03CD44\u589e\u5f3a\u5375\u5de2\u764c\u5bf9\u5316\u7597\u7684\u654f\u611f\u6027<\/b><\/p>\n<ul type=\"disc\">\n<li>\u6458\u8981\/\u6d77\u62a5\u7f16\u53f7\uff1a968 <\/li>\n<li>\u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5 <\/li>\n<li>\u5206\u4f1a\u573a\u6807\u9898\uff1aBiological Therapeutic Agents<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u751f\u7269\u6cbb\u7597\u836f\u7269<\/li>\n<\/ul>\n<p><b>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/b><\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u5904\u4e8e\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u6700\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67098\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216 MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u53ca\u6fb3\u5927\u5229\u4e9a\u5f00\u5c5540\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cdHQP1351\u5df2\u5728\u4e2d\u56fd\u9012\u4ea4\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff0c\u8be5\u54c1\u79cd\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5ba1\u8bc4\u5feb\u901f\u901a\u9053\u53ca\u5b64\u513f\u836f\u8ba4\u8bc1\u8d44\u683c\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9710\u9879FDA\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u8bc1\u3002<\/p>\n<p><b>\u524d\u77bb\u6027\u58f0\u660e<\/b><\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">  <\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"s3WRPaVIR5\"><p><a href=\"https:\/\/www.ascentagepharma.com\/\">A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions&#8221; &#8212; Ascentage Pharma\" src=\"https:\/\/www.ascentagepharma.com\/embed\/#?secret=s3WRPaVIR5\" data-secret=\"s3WRPaVIR5\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e743\u670811\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u7814\u53d1\u4f01\u4e1a&#8211;\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u6d89\u53ca\u4e94\u4e2a\u539f\u521b\u65b0\u836f\u7684\u516d\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55\u5165\u90092021\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\uff0c\u6458\u8981\u5185\u5bb9\u5df2\u5728AACR\u5b98\u7f51\u516c\u5e03\u3002\u672c\u6b21AACR\u5e74\u4f1a\u5c06\u4e8e\u7f8e\u56fd\u4e1c\u90e8\u65f6\u95f44\u670810\u65e5-15\u65e5\u30015\u670817\u65e5-21\u65e5\u4ee5\u865a\u62df\u4f1a\u8bae\u5f62\u5f0f\u4e3e\u884c\u3002 \u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u662f\u5168\u7403\u5386\u53f2\u6700\u60a0\u4e45\u3001\u89c4\u6a21\u6700\u5927\u7684\u80bf\u7624\u7814\u7a76\u5b66\u672f\u4f1a\u8bae\u4e4b\u4e00\u3002\u4f1a\u8bae\u5173\u6ce8\u9ad8\u8d28\u91cf\u80bf\u7624\u7814\u7a76\u53ca\u521b\u65b0\u7684\u5404\u4e2a\u65b9\u9762\uff0c\u662f\u5168\u7403\u80bf\u7624\u7814\u7a76\u7684\u7126\u70b9\uff0c\u5c06\u6c47\u96c6\u80bf\u7624\u9886\u57df\u7684\u6700\u524d\u6cbf\u7684\u7814\u7a76\u6210\u679c\u3002 \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u201c\u5f88\u9ad8\u5174\u516c\u53f8\u7684\u591a\u4e2a\u65b0\u836f\u9879\u76ee\u5df2\u8fde\u7eed\u591a\u6b21\u5165\u9009AACR\u5e74\u4f1a\uff0c\u672c\u6b21AACR\u5c55\u793a\u7684\u6210\u679c\u4e3b\u8981\u805a\u7126\u4e8e\u516c\u53f8\u591a\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u7684\u91cd\u8981\u54c1\u79cd\u7684\u8f6c\u5316\u7814\u7a76\u3002\u8fd9\u4e9b\u7814\u7a76\u6709\u52a9\u4e8e\u6211\u4eec\u66f4\u597d\u5730\u4e86\u89e3\u836f\u7269\u4f5c\u7528\u673a\u5236\u3001\u786e\u5b9a\u6709\u6548\u7684\u8054\u5408\u5e94\u7528\uff0c\u4ee5\u53ca\u53d1\u73b0\u65b0\u7684\u9002\u5e94\u75c7\uff0c\u4ece\u800c\u8fdb\u4e00\u6b65\u63a8\u8fdb\u516c\u53f8\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u7a0b\u3002\u201d \u4e9a\u76db\u533b\u836f\u516d\u9879\u7814\u7a76\u6210\u679c\u5165\u9009AACR\u58c1\u62a5\u5c55\u793a\u5982\u4e0b\uff1a \u6807\u9898\uff1a BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) synergistically induces apoptosis and inhibits tumor growth in preclinical models of acute myeloid leukemia and myelodysplastic syndromes (AML\/MDS) BCL-2\u6291\u5236\u5242APG-2575\u548c\u9ad8\u4e09\u5c16\u6749\u916f\u78b1(HHT)\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u548c\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81(MDS)\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u8bf1\u5bfc\u7ec6\u80de\u51cb\u4ea1\u548c\u6291\u5236\u80bf\u7624\u751f\u957f\u7684\u534f\u540c\u4f5c\u7528 \u6458\u8981\/\u6d77\u62a5\u7f16\u53f7\uff1a981 \u5206\u4f1a\u573a\u7c7b\u522b\uff1aExperimental and Molecular Therapeutics&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u5b9e\u9a8c\u6027\u4e0e\u5206\u5b50\u7597\u6cd5 \u5206\u4f1a\u573a\u6807\u9898\uff1aCell Death Pathways and Treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u4e0e\u6cbb\u7597 \u6807\u9898\uff1a Inhibition of BCL-2 (by APG-2575) and CDK4\/6 synergistically induces&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021031107310022437\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-22437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/22437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=22437"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/22437\/revisions"}],"predecessor-version":[{"id":22438,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/22437\/revisions\/22438"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=22437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=22437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=22437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}